#165 Investor Presentation FY 2021-22 Barugs BETA DRUGS LTD.#2Barugs BETA DRUGS LTD. Disclaimer • • This corporate presentation has been prepared by Beta Drugs Limited (the "Company") solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation should not be construed as legal, tax, investment or other advice. This presentation is confidential, being given solely for your information and for your use, and may not be copied, distributed or disseminated, directly or indirectly, in any manner. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company. The information contained in this presentation is only current as of its date and has not been independently verified/ authenticated and are based upon to the best of the knowledge, belief and information. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such revision or changes. No representation, warranty, guarantee or undertaking, express or implied, is or will be made as to, and no reliance should be placed on, the accuracy, completeness, correctness or fairness of the information, estimates, projections and opinions contained in this presentation. None of the Company or any of its affiliates, advisers or representatives accept any liability of whatsoever nature for any loss howsoever arising from any information presented or contained in this presentation. Please note that the past performance of the Company is not, and should not be construed as, indicative of future results. This presentation does not constitute or form part of and should not be construed as, directly or indirectly, any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of Beta Drugs Limited by any person in any jurisdiction, including in India or elsewhere, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any investment decision or any contract or commitment therefore.. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, or any other applicable law in India. We undertake no obligation arising out of this information or any consequence arising therefrom.#3Formulations and API Plant BETA DRUGS LTD. Address: KHARUNI-LODHI MAJRA ROAD,VILL.NANDPUR, BADDI- 174101 DIST-SOLAN (HP) 01 WHO- GMP plant & other international accreditations. Triggered for ANVISA, INVIMA & PICS ADLEY FORMULATION PVT LTD. Address: VILLAGE KOTLA, P.O. BAROTIWALA,SOLAN (HP)-174103 WHO-GMP facility for tablets, capsules, Injection & Pre-Filled Syringes 02 "State of Art" manufacturing facilities Dedicated to Oncology 04 70 03 Address: Tashkent region, Bekabad city, Uzbekistan MSG, Sirdarya street, 8 First Indian Oncology plant in Uzbekistan. Established in 2018 in JV with SILUJIN Pvt Ltd. Address: BETA Brugs DRUGS LTD. Beta UBK International(P) Ltd. ADLEY LAB LTD. : API Plant D-27 FOCAL POINT DERA BASSI SAS Nagar PUNJAB WHO-GMP, API manufacturing facility. Adley Lab Ltd. 3#4Unique value propositions дю BETA Brugs DRUGS LTD. Diversified Oncology portfolio ET 6'9 Lung Cancer Head & Neck Cancer Colorectal Cancer Strong Future pipeline Rich product pipeline of 23 products Differentiated Science/Innovation Working on ⚫NDDS •TKIs •Proteasome inhibitors •PARP inhibitors Backwardly Integrated BDL is among the few companies that work across the value chain Developed API of 90% of own brands Breast Cancer Gastric Cancer Ав 360 Brain Tumor Testicular Cancer Renal Cancer Ovarian Cancer Leukemia Lymphoma Myeloma Supportive Prostate Cancer Hemat Solid 2021 2022 2023 2024 2025 2026 3 2 NIB'S New Drug Delivery System PARP Inhibitors 4#5Innovation is driving growth- New product development is our core competency BETA Brugs DRUGS LTD. Expertise in NDDS (New Drug Delivery System) Proven experience in managing complex product development- Azacitidine Oral, Ready to Use Gemcitabine & Docetaxel R&D expenditure (Value in Crs) 1.3 2.5 Working on FTLs- 1st product to be launched in Q2 FY'22 FY'21 FY'22 Pipeline of 23 Products which are going to be off-patent in next 5 Years 5#6Healthy Growth across all verticals in FY'22 Domestic Own brand ()) 두 International 67% revenue growth 15% revenue growth API BETA Brugs DRUGS LTD. Contract Manufacturing 65% revenue growth 67% revenue growth . 9 New product launches New key accounts conversions Geographical expansion Consolidation of existing business New product launches New customer addition & consolidate sales from existing customers New formulations Added new logos & consolidated sales from existing customers 6#7Domestic Own Brand Finished Formulation Sales (% Growth) % Growth 33% 18% 67% Brands continue to 2 occupy No1 Position Barugs BETA DRUGS LTD. 9 New products launched in FY21-22 Vision to grow at CAGR of 30% NDDS has been 1 launched MDS-O FY 19-20 FY 20-21 FY 21-22 6 Brands achieved top 5 position in respective market#8Domestic Own Brand Beta drugs Limited has strong position in the Indian market with 110 SKUs. Products are available in major Corporate & Govt hospitals 69 Solid Tumor Breast Cancer Lung Cancer 35 Hematology Barugs BETA DRUGS LTD. стро Head & Neck Colorectal Cancer Ovarian Cancer Cancer 999 GÐ Gastric Cancer Brain Tumor Testicular Cancer Renal Cancer Prostate Cancer 18 Leukemia Lymphoma Myeloma Supportive 10 Supportive#9Domestic Own Brand Barugs BETA DRUGS LTD. New Brands Launched in 2021-22 ADXATE Methotrexate Inj.500mg/1g INOTAD Irinotecan Inj.40/100mg KABONIB™ Cabozantinib Tablets 60mg | 40mg | 20mg AFADEL Afatinib Tablets 20/30/40mg CAXFILA Megestrol Acetate Tablets 160 mg NINTAD Nintedanib Cap. 100/150mg Pazotab Pazopanib Tablets 200/400mg MDS-O Azacitidine Tablets 200/300 mg CARFIMIB Carfilzomib Inj 60mg/vial Solid Tumor ADSUNIB Sunitinib Capsules 12.5/25/50mg ADLEAP Enzalutamide Capsules 40mg Adlante Gem-RTU Lenvatinib Capsules 4/10 Mg HER-TINIB Lapatinib Tablets 250 mg AB-PACLI Paclitaxel Protein-Bound 100 mg ADMIDE Bicalutamide Tablets 50mg HERUCA Rucaparib Tablets 200/300mg Gemcitabine Inj 200mg/1g/1.4g (Ready to Use) ADTRINIB Sorafenib Tablets 200 mg ADPAXIL Paclitaxel Inj 30/100/260/300mg ARBAZ Cabazitaxel Inj 60mg AFADEL Afatinib Tablets 20/30/40mg BEXINIB Axitinib Tablets 1/5mg AMGICIN Gemcitabine Inj 200/1000mg RTU-DOCE Docetaxel Inj (Ready to Use) FISTENT Fulvestrant In) (250 mg/5 ml) Hematological Care BEEDAN Dasatinib Tablets 20/50/70/100mg PEG-LASGEN Peg L-asparaginase Inj 3750 IU BORTIAD Bortezomib Inj 2mg ADMINE Imatinib Tablets 100/400 mg L-ASGEN L-Asparaginase Injection 5000/10000 IU ADLINOD Lenalidomide 5/10/25mg. Supportive Care ADFILL Pegfilgrastim Inj 6mg ADGRAM Granisetron Hydrochloride Inj EMETANT-IV Fosaprepitant Inj 150mg ALZIC Zoledronic Inj 4mg ADBIRON Abiraterone Tablets 250mg KABONIB Cabozantinib Tablets 60/40/20mg CAPAD Capecitabine Tablets 500mg ADGEF Gefitinib Tablets 250mg ADPEM Pemetrexed Inj 100/500 mg LETRAFEM Letrazole Tablet 2.5mg ADSIDE Etoposide 50mg Cap/ 100mg Inj. Pazotab Pazopanib Tablets 200/400mg ADOXI Docetaxel Inj 20/80/120mg ERLOTAD Erlotinib Tablets 100/150mg ADCARB Carboplatin Inj 150/450mg ADNAST Anastrozole Tablet Img ADVIN Vinorelbine Inj 50 mg NINTAD Nintedanib Cap. 100/150mg ADPLATIN Oxaliplatin Injection 50/100mg TEMOZAD Temozolomide Capsules 20/100/250 mg ADCIST Cisplatin Inj 10/50mg ADRICIN Epirubicin Inj 10/50mg INOTAD Irinotecan Inj 100mg/5ml ADRIB Doxorubicin Inj 10/50mg MDS PLUS ADXATE ADRICIN ADSIDE Azacitidine Inj 100mg Methotrexate 2.5mg Tablets Epirubicin Inj 10/50mg Etoposide 50mg Cap/ 100mg Inj. Plerixafor Inj 24 mg Thalidomide Capsule 50/100mg Fludarabine Inj 50ml BUSFAN Busulfan Inj 60mg ADSTEM ADTHAL ADFLU ADBEN ADCYCLO MDS-O CARFIMIB Bendamustine Inj 100mg Cyclophosphamide Tablets 50mg Azacitidine Tablets 200/300 mg EMETANT Aprepitant Capsules 125/80mg Adcumin BIO-AVAILABLE NANOCURCUMIN ADCUMIN ROYALE ORA-RINZ CAXFILA Megestrol Acetate Tablets IP Carfilzomib Inj 60mg/vial ADDCURE Advanced Treatment Formula For Radiation Dermatitis#10Road map for Domestic branded market in FY'23 Strengthen product basket C Increasing customer base Market penetration Talent acquisition Adding 4 new FTL / FFTL products Focus on New hospital entries. Focus on Millennial Dr's Increasing presence in tier 2 & tier 3 cities Hiring the best people for uncovered territories BETA Brugs DRUGS LTD. 1#11International Market International Market FY 20-21 15% growth FY 21-22 Triggered for ... invima Instituto Nacional de Vigilancia de Medicamentos y Alimentos. ANVISA PIC/S Our Accreditations TURING PR PRODUCT QUALITY IONAL AGENCY FOR FOOD AND D NAFDAC MINISTRATION National Medicines Regulatory Authority (NMRA) Ministry of Health, Nutrition & Indigenous Medicine FDAM DPML Food and Drug Administration PHILIPPINES Direction de la Pharmacie, du Médicament et des Laboratoires de Côte d'Ivoire TMDA Government of Nepal Ministry Of Health and Population Tanzania Medicines & Medical Devices Authority BETA Brugs DRUGS LTD. GANDA KINGDOM OF CAMBODIA NATION-RELIGION-RING ONAL CRUS AUTHORITY Sale Drugs Save Lives 0 MINISTRY OF HEALTH National Maternal and Odd Health Centre National profeteealth Programm REPUBLIC OF KENYA MINISTRY OF HEALTH PHARMACY AND POISONS BOARD Food, Medicine and Healthcare Administration and Control Authority of Ethiopia Globally represented by our subsidiaries or sales partners in 18 Countries More than 50 products registered#12cuador Geographical expansion Plan by FY'25 Guyana Venezuela Suriname French Guiana Colombia Peru Bolivia Argentina Paraguay Brazil Uruguay LatAm No. of targeted countries: 9 Total market size: ~ $30 mn Expected business by FY'25: $4 mn W. Sahara Algeria Libya Egypt Mauritania Mall Niger Eritrea Sudan Chad Dibouti Cabo Verde Senegal Gambia Guinea-Bissau Guines Sierra Leone Liberia Cote d'ivoire Chana Toga Burkina Nigeria Somaliland Ethiopia Central African Rep 5. Sutan Benin Es Guined 5 Somalia São Tomé and Principe Gabon Dem. Rep. Congo Burundi Tanzania Comoros gandy Rwanda Kenya Seychelles Angola Namibia Zambia Zimbabwe Botswana Mozambique eSwatini South Africa Lesotho Mauritius AFRICA No. of targeted countries: 8 Total market size: ~ $ 15 mn Expected business by FY'25: $2 mn Kazakhstan Armenia Turkey Georgia Azerbaijan Kyrgyzstan Turkmenistan Tajikistan Cyprus Syria Iran Afghanistan Lebanon State of i Iraq Kuwait Israel Palestine Jordan Bahrain Pakistan Saudi Arabia UAE India Oman Yemen - Maldives Sri Lanka Moldova -Belaras Ukraine Georgia Armenia- Turkmenistan- Kazakhstan Russia Mongolia North Korea China South Korea Taiwan Bang yan Macao ladesh Hong Kong Thailand Vietnam Philippines -Uzakistan Kyrgyzstan Tajikistan Cambodial Malaysia Russia Indonesia East Timor ASIA BETA Brugs DRUGS LTD. No. of targeted countries: 5 Japan Total market size: ~$15 mn Expected business by FY'25: $2 mn CIS No. of targeted countries: 5 Total market size: ~ $6 mn Expected business by FY'25: $2 mn#13Strong In-House API Development BETA Brugs DRUGS LTD. 65 % growth FY 20-21 FY 21-22 BDL has got an allotment of 14 Acres of land on 95 years lease in a special area allocated for API & intermediates, where there is a single-window approval from the pollution department. The company has a plan to expand its API business along with new formulations in the coming years Highlights of FY 2021-22 Received WHO-GMP approval •The company is aggressively working to file its first CEP (Europe) by October 2022 • Captive expansion- Adding 1 more line by Aug'22 and focusing on EU GMP. ⚫13 New products developed in FY21-22 BDL is among very few companies to develop API of Carfilzomib, Cabozantinib, Afatinib, Pazopanib & Rucaparib Received DCGI approval of Cabozantinib DCGI approval is expected for Rucaparib 1#14Strong In-House API Development SOLID TUMOR ANASTROZOLE AXITINIB BICALUTAMIDE DOCETAXEL TRIHYDRATE ENZALUTAMIDE ERLOTINIB HYDROCHLORIDE FULVESTRANT GEFITINIB LAPATINIB LENVATINIB METHOTREXATE NINTEDANIB PAZOPANIB PEMETREXED SORAFENIB SUNITINIB TEMOZOLOMIDE IRINOTICAN AFATINIB CABOZANTINIB HEMATOLOGY AZACITIDINE AZACITIDINE- ORAL BENDAMUSTINE BORTEZOMIB SUPPORTIVE APREPITANT FOSAPREPITANT ZOLEDRONIC ACID DASATINIB HYDROXYUREA IMATINIB LENALIDOMIDE PLERIXAFOR CARFILZOMIB API Under Development PALBOCICLIB ERIBULIN CERITINIB ELTROMBOPAG RUCAPARIB BETA Brugs DRUGS LTD.#15Our CRAM Partners Trusted Partners ✓ Partnership with 50+ companies ✓ Partnership expected with 3 more Indian MNC in FY'23 We value our CRAM partners Sustained growth Important clients FY 20-21 67% growth FY 21-22 Zydus CADILA INTAS dedicated elife PHARMACEUTICALS LIMITED The Care Continue RPG LIFE SCIENCES LIMITED ALKEM n torrent PHARMA BETA Brugs DRUGS LTD. Reliance CAPLIN POINT LABORATORIES LTD. BDR N AUREATE Shilpa Shilpa Medicare Ltd. HETERO HETERO Zuventus Panacea Biotec Healthcare Ltd. LIFE SCIENCES 1#16Healthy growth in Revenue & Profit REVENUE FY'22 Consolidated FY'21 FY'22 growth (Rs Cr) (Rs Cr) Total revenue 116.12 183.84 58% EBITDA 25.24 43.46 72% EBITDA % 21.7% 23.6% 190 bps PAT 11.7 24.8 112% PAT % 10.10% 13.51% 341 bps BETA Brugs DRUGS LTD. 1#17Financial performance % EBITDA 20.2% 18.5% 23.6% 21.7% % Operating/EBITDA 19.7% 16.0% 15.8% 14.2% FY'19 FY'20 FY'21 FY'22 FY'19 FY'20 FY'21 FY'22 Current ratio 2.0 2.0 1.5 1.3 FY'19 FY'20 FY'21 FY'22 BETA Brugs DRUGS LTD.#18Solvency Ratio Debt ratio 0.24 0.21 0.15 0.13 FY'19 FY'20 FY'21 FY'22 Interest coverage ratio 7.6 6.5 5.6 0.48 Debt to equity ratio 0.39 0.26 0.21 BETA Brugs DRUGS LTD. FY'19 FY'20 FY'21 FY'22 19.1 FY'19 FY'20 FY'21 FY'22#19FY'23 Road Map Capacity expansion: • • Lypholizer capacity increased to 3 folds in Beta drugs plant Separate lypholized injectable manufacturing facility for general injectable in Adley formulations plant (Cardiovascular, Antifungal, immunosuppressant) Barugs BETA DRUGS LTD. Domestic Market International market ΑΡΙ 5 New developments Plan to launch 4 new products FGMP accreditations Untapped market Improving PCPM Consolidate institutional business Geographical expansion Commercialization of products under registration Planning to file CEP by Oct 2022 New partnerships CMO Consolidating existing business New product addition with existing partners Partnership with 3 new Indian MNC#20Innovative product development is a result of our continuous efforts. Contacts Email: [email protected] Barugs BETA DRUGS LTD.